Nykredit A S bought a new position in shares of DaVita Inc. (NYSE:DVA – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The fund bought 4,774 shares of the company’s stock, valued at approximately $1,062,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Legacy Financial Advisors Inc. acquired a new stake in shares of DaVita in the 2nd quarter valued at approximately $303,000. BTG Pactual Asset Management US LLC bought a new position in DaVita in the 2nd quarter valued at approximately $254,000. Sigma Planning Corp acquired a new stake in DaVita in the second quarter valued at approximately $209,000. Benjamin Edwards Inc. acquired a new stake in DaVita in the second quarter valued at approximately $284,000. Finally, Cookson Peirce & Co. Inc. grew its stake in shares of DaVita by 8.2% during the second quarter. Cookson Peirce & Co. Inc. now owns 1,602 shares of the company’s stock worth $356,000 after buying an additional 122 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on DVA. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 price objective on shares of DaVita in a research report on Wednesday, August 5th. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Barclays increased their target price on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Finally, Oppenheimer set a $220.00 price target on DaVita in a research note on Friday, August 7th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, DaVita currently has an average rating of “Hold” and a consensus price target of $221.75.
DaVita Stock Performance
NYSE:DVA opened at $183.87 on Tuesday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The company has a 50 day simple moving average of $207.91 and a two-hundred day simple moving average of $184.77. The company has a market capitalization of $11.73 billion, a PE ratio of 15.05, a P/E/G ratio of 0.48 and a beta of 0.83.
DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same period in the prior year, the firm posted $2.95 EPS. The company’s quarterly revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts predict that DaVita Inc. will post 14.57 EPS for the current year.
Insider Transactions at DaVita
In related news, insider Kathleen Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.90% of the stock is currently owned by insiders.
DaVita Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Featured Stories
- Five stocks we like better than DaVita
- 3 Under-the-Radar Defense Stocks With Record Backlogs
- This Korea ETF Has Soared, But the Rally May Not Be Over
- Why Guidewire’s Post-Earnings Plunge May Not Last
- Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
